- Citing first mover advantage, Goldman Sachs analyst Dana Flanders is "confident" in his sales forecast for Horizon Pharma's (NASDAQ:HZNP) Krystexxa (pegloticase) despite the potential threat from Selecta Biosciences' (NASDAQ:SELB) SEL-212. Updated data from an ongoing mid-stage study will be presented at ACR in October.
- Both are uricase treatments but Selecta says SEL-212 is the only one that avoids immunogenicity.
- Krystexxa has been on the U.S. market since September 2010.
- Previously: Selecta Biosciences' SEL-212 shows positive effect in mid-stage gout study (June 15)
Goldman confident with sales forecast for Horizon Pharma's gout drug Krystexxa despite potential threat from Selecta Bio's SEL-212
Recommended For You
More Trending News
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
HZNP | - | - |
Horizon Therapeutics Public Limited Company |